Aljosja Rogiers
Overview
Explore the profile of Aljosja Rogiers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
1472
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Fendler A, Shepherd S, Au L, Wu M, Harvey R, Schmitt A, et al.
Lancet
. 2022 Jan;
399(10328):905-907.
PMID: 35090602
No abstract available.
12.
Fendler A, Shepherd S, Au L, Wilkinson K, Wu M, Schmitt A, et al.
Cancer Cell
. 2021 Dec;
40(2):114-116.
PMID: 34968417
No abstract available.
13.
Fendler A, Shepherd S, Au L, Wilkinson K, Wu M, Byrne F, et al.
Nat Cancer
. 2021 Dec;
2:1321-1337.
PMID: 34950880
CAPTURE (NCT03226886) is a prospective cohort study of COVID-19 immunity in patients with cancer. Here we evaluated 585 patients following administration of two doses of BNT162b2 or AZD1222 vaccines, administered...
14.
Marin-Bejar O, Rogiers A, Dewaele M, Femel J, Karras P, Pozniak J, et al.
Cancer Cell
. 2021 Jun;
39(8):1135-1149.e8.
PMID: 34143978
Therapy resistance arises from heterogeneous drug-tolerant persister cells or minimal residual disease (MRD) through genetic and nongenetic mechanisms. A key question is whether specific molecular features of the MRD ecosystem...
15.
Rogiers A, Pires da Silva I, Tentori C, Tondini C, Grimes J, Trager M, et al.
J Immunother Cancer
. 2021 Jan;
9(1).
PMID: 33468556
Background: Patients with cancer who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are more likely to develop severe illness and die compared with those without cancer. The...
16.
Bell C, Fennell K, Chan Y, Rambow F, Yeung M, Vassiliadis D, et al.
Nat Commun
. 2019 Jun;
10(1):2723.
PMID: 31222014
Non-genetic drug resistance is increasingly recognised in various cancers. Molecular insights into this process are lacking and it is unknown whether stable non-genetic resistance can be overcome. Using single cell...
17.
Corre S, Tardif N, Mouchet N, Leclair H, Boussemart L, Gautron A, et al.
Nat Commun
. 2018 Nov;
9(1):4775.
PMID: 30429474
BRAF inhibitors target the BRAF-V600E/K mutated kinase, the driver mutation found in 50% of cutaneous melanoma. They give unprecedented anti-tumor responses but acquisition of resistance ultimately limits their clinical benefit....
18.
Rambow F, Rogiers A, Marin-Bejar O, Aibar S, Femel J, Dewaele M, et al.
Cell
. 2018 Jul;
174(4):843-855.e19.
PMID: 30017245
Many patients with advanced cancers achieve dramatic responses to a panoply of therapeutics yet retain minimal residual disease (MRD), which ultimately results in relapse. To gain insights into the biology...
19.
Talebi A, Dehairs J, Rambow F, Rogiers A, Nittner D, Derua R, et al.
Nat Commun
. 2018 Jun;
9(1):2500.
PMID: 29950559
Whereas significant anti-tumor responses are observed in most BRAF-mutant melanoma patients exposed to MAPK-targeting agents, resistance almost invariably develops. Here, we show that in therapy-responsive cells BRAF inhibition induces downregulation...
20.
Higham C, Dombi E, Rogiers A, Bhaumik S, Pans S, Connor S, et al.
Neuro Oncol
. 2018 Feb;
20(6):818-825.
PMID: 29409029
Background: Neurofibromatosis 1 (NF1) leads to the development of benign and malignant peripheral nerve sheath tumors (MPNST). MPNST have been described to develop in preexisting benign plexiform neurofibromas (PN) and...